Pragasam Viswanathan
VIT University, India
Posters-Accepted Abstracts: J Diabetes Metab
Aim: This study was designed to analyze the level of soluble CD36 (sCD36) in both plasma and urine of type 2 diabetic patients with and without micro-albuminuria/macro-albuminuria. Methods: Study subjects (n=20 each) comprised of those with normal glucose tolerance, type 2 diabetes (T2DM) with normoalbuminuria, T2DM with micro-albuminuria and T2DM with macro-albuminuria. The biochemical parameters were analyzed using auto-analyzer and the level of sCD36 was estimated using an in-house Sandwich ELISA. Results: The presence of sCD36 has been identified for the first time in the urine sample. Significant increase in the level of sCD36 was observed in both plasma and urine of diabetic patients with micro-albuminuria (P<0.01) and macro-albuminuria (P<0.001). Positive correlation of sCD36 with the kidney markers such as urea, creatinine and e-GFR confirmed the association of sCD36 with kidney damage in diabetic patients. Micro-albuminuria, which is clinically used as a biomarker for nephropathy showed a strong positive correlation with urine sCD36 (r=0.642; P<0.001) and plasma sCD36 (r=0.498; P<0.001) in Pearson correlation analysis, which was further substantiated in stepwise multiple regression analysis. Conclusions: Our study implies a plausible prognostic/adjuvant biomarker role of soluble CD36 for diabetic nephropathy.
Email: pragasam.v@vit.ac.in
